During the medac satellite symposium at the annual congress of the European Alliance of Associations for Rheumatology (EULAR) 2022, Prof Burmester from Germany presented a recent study that suggests that briefly pausing methotrexate (MTX) improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. The speakers Prof Feist (Germany), Prof Østergaard (Denmark) and Dr Koduri (UK) presented MTX combination therapies and reported on how to realise good patient adherence during the treatment of rheumatoid arthritis (RA).
- Prof Mikkel Osterggard (Denmark): Role of subcutaneous methotrexate in the treatment of patients with RA
- Prof Gerd Burmester (Germany): RA therapy with methotrexate during the COVID vaccination
- Prof Eugen Feist (Germany): Combination therapy with methotrexate, the “bodyguard of biologics”
- Dr Gouri Koduri (UK): Improving patient adherence during the treatment of RA
Disclosures:
- Prof Burmester: Support for clinical trials and projects: Abbvie, Amgen, BMS, Gliead/Galapagos, Janssen, Lilly, MSD, Novartis, Roche, Pfizer, UCB, German Research Foundation, BMBF, Senate of Berlin/DRFZ Lectures and consulting fees: Abbvie, Amgen, BMS, Janssen, Galapagos, medac, Novartis, MSD, Lilly, Pfizer, Roche, UCB Honorary reviewer activities: German Research Foundation, BMBF, EULAR, Dutch Rheumatism Fund, Versus Arthritis UK
- Prof Østergaard: Research grants from: Abbvie, Amgen, BMS, Merck, Celgene Novartis Speaker and/or consultancy fees from: Abbvie, MS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, medac, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, UCB
- Prof Feist: Abbvie, AB2Bio, BMS, Celgene, Janssen, Lilly, medac, MSD, Novartis, Pfizer, Roche/Chugai, Sanofi, Sobi, UCB
- Dr Koduri: Roche, medac, Boehringer-Ingelheim
